Evidence map›Paper›PMID 40679256›Full record

ArticleHuman vaccines & immunotherapeutics2025

Hyponatremia predicts immunotherapy resistance in biliary tract cancer.

Tiance Wang, Zijian Lv, Runjia Fan, Weidong Han, Qian Mei

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tiance WangDepartment of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Zijian LvDepartment of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Runjia FanDepartment of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Weidong HanDepartment of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Qian MeiDepartment of Bio-Therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.ORCID 0009-0006-9605-5293

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia, a common electrolyte imbalance in cancer patients, has frequently been disregarded in terms of its prognostic implications for immunotherapy. This study examined the prognostic implications of pre-treatment hyponatremia in patients with biliary tract cancers (BTC) undergoing immunotherapy. We retrospectively included 112 BTC patients who received immune checkpoint inhibitors (ICIs) treatment from August 2016 to December 2024, with an average follow-up period of 11.25 months. In accordance with the diagnosis of hyponatremia before the first ICIs treatment, patients were divided into two distinct groups. There were no significant differences in age (OR = 0.6, 95% CI, 0.2-1.8) or gender distribution (OR = 0.8, 95% CI, 0.3-2.4). Kaplan-Meier curves and the Mantel-Haenszel log-rank test were utilized to compare progression-free survival (PFS) and overall survival (OS) among groups. Cox and logistic regressions were employed to analyze the relationship between serum sodium levels and prognosis in 112 BTC patients, considering baseline characteristics. Patients with hyponatremia demonstrated reduced PFS (6 vs. 9 months,

Indexed as

Biliary Tract NeoplasmsDrug Resistance, NeoplasmHyponatremiaImmune Checkpoint InhibitorsImmunotherapyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSodiumImmune Checkpoint InhibitorsSodiumbiliary tract cancersbiomarkerHyponatremiaimmunotherapyretrospective

Identifiers

PMID40679256
PMCPMC12279278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.